Showing 1711-1720 of 2054 results for "".
- RevOpsis Names Emmett Cunningham, MD, PhD, to Strategic Advisory Boardhttps://modernod.com/news/revopsis-names-emmett-cunningham-md-phd-to-strategic-advisory-board/2482273/RevOpsis Therapeutics announced the appointment of Emmett Cunningham, MD, PhD, to its Strategic Advisory Board (SAB) and as a private investor. Dr. Cunningham brings more than 20 years of experience as a full-time entrepreneur and investor to his new role with RevOpsis. Dr. Cunning
- Heidelberg Engineering to Showcase New Imaging Technology at ARVOhttps://modernod.com/news/heidelberg-engineering-to-showcase-new-imaging-technology-at-arvo/2482254/At the upcoming ARVO meeting in Seattle, Heidelberg Engineering will showcase a wide range of imaging applications from basic vision research to clinical trials and guided therapy. SeeLuma For the first time, Heidelberg Engineering will demonstrate
- SpyGlass Pharma Unveils 1-Year Data of Its Drug Delivery Platform Implanted During Routine Cataract Surgery in Eyes with Glaucomahttps://modernod.com/news/spyglass-pharma-unveils-1-year-data-of-its-drug-delivery-platform-implanted-during-routine-cataract-surgery-in-eyes-with-glaucoma/2482196/SpyGlass Pharma announced 1-year follow up data from a first-in-human study of 23 patients with glaucoma or ocular hypertension implanted with SpyGlass’ IOL-based drug delivery platform with bimatoprost at the time of cataract surgery. These data will be highlighted in a poster presentation
- Swiss Advanced Vision Launches New Features for its Toric Calculatorhttps://modernod.com/news/swiss-advanced-vision-launches-new-features-for-its-toric-calculator/2482130/Swiss Advanced Vision (SAV-IOL) announced the launch of new features for its toric calculator designed to improve the calculation experience. For the first-time, ophthalmologists will be able to use a web-based configurator to help define the best incision location to minimize resi
- DigitalOptometrics Launches DOT Translation Servicehttps://modernod.com/news/digitaloptometrics-launches-dot-translation-service/2482073/DigitalOptometrics announced the launch of “DOT” (DigitalOptometrics Translate), a new translation service that aims to improve patient care. “DOT” is a real-time translation technology that breaks language barriers, allowing eye care professionals to commun
- Regenxbio Announces Interim Data from Phase 2 AAVIATE Trial of ABBV-RGX-314 for Wet AMD Using Suprachoroidal Deliveryhttps://modernod.com/news/regenxbio-announces-interim-data-from-phase-2-aaviate-trial-of-abbv-rgx-314-for-the-treatment-of-wet-amd-using-suprachoroidal-delivery/2482066/Regenxbio announced positive interim data from the phase 2 AAVIATE trial of ABBV-RGX-314 for the treatment of wet age-related macular degeneration (AMD) using suprachoroidal delivery. Investigational ABBV-RGX-314 is designed to be a one-time, in office treatment that has the potent
- Clearside Biomedical Completes Randomization in Phase 2b Clinical Trial of CLS-AX in Wet AMDhttps://modernod.com/news/clearside-biomedical-completes-randomization-in-phase-2b-clinical-trial-of-cls-ax-in-wet-amd/2482013/Clearside Biomedical announced it has completed randomization in its ODYSSEY Phase 2b clinical trial of CLS-AX (axitinib injectable suspension) in wet age-related macular degeneration (AMD). Topline data results are expected in the third quarter of 2024. “As we continue
- Tarsus Announces Topline Phase 2a Trial Results Evaluating TP-03 for the Treatment of MGD in Patients with Demodex Miteshttps://modernod.com/news/tarsus-announces-topline-phase-2a-trial-results-evaluating-tp-03-for-the-treatment-of-mgd-in-patients-with-demodex-mites/2482004/Tarsus Pharmaceuticals announced topline results from the Ersa phase 2a clinical trial evaluating TP-03 (lotilaner ophthalmic solution, 0.25%) administered twice daily (BID) or three times a day (TID) for 12 weeks for the treatment of meibomian gland disease (MGD) in patients with Demodex&nb
- Regenxbio Presents New Data on Investigational AAV Therapeutic for Retinal Conditionshttps://modernod.com/news/regenxbio-presents-new-data-on-investigational-aav-therapeutic-at-aao/2481967/At the American Academy of Ophthalmology 2023 Annual Meeting in San Francisco, new data was presented for Regenxbio's ABBV-RGX-314, an investigational one-time AAV therapeutic being developed in collaboration with AbbVie for the treatment of wet age-related macular degener
- Pixium Vision Announces the Launch of a Process to Find Buyershttps://modernod.com/news/pixium-vision-announces-the-launch-of-a-process-to-find-buyers/2481900/Pixium Vision SA announced that a tender process (appel d’offres) for the purpose of finding buyers to acquire the company's business will be published October 19. Unable to find financial investors within the restricted timeframe and in line with the company's n